Who is sponsoring NCT00026338?

NCT00026338 is sponsored by NCIC Clinical Trials Group.

What condition does NCT00026338 study?

NCT00026338 studies Pancreatic Cancer.

What drugs are being tested in NCT00026338?

Interventions: erlotinib hydrochloride, gemcitabine hydrochloride.

What is the status of NCT00026338?

NCT00026338 is currently COMPLETED.

Last reviewed 2020-04-02 · How we verify

Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer

NCT00026338 PHASE3 COMPLETED

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as erlotinib use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy and biological therapy may kill more tumor cells. It is not yet known if gemcitabine is more effective with or without erlotinib in treating pancreatic cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of gemcitabine with and without erlotinib in treating patients who have unresectable locally advanced or metastatic pancreatic cancer.

Details

Lead sponsor	NCIC Clinical Trials Group
Phase	PHASE3
Status	COMPLETED
Enrolment	569
Start date	Mon Oct 29 2001 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Feb 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Pancreatic Cancer

Interventions

erlotinib hydrochloride
gemcitabine hydrochloride

Countries

Hong Kong, Italy, Poland, New Zealand, Belgium, Mexico, United States, Greece, Chile, Israel, Argentina, Canada, Romania, Brazil, United Kingdom, Germany, Australia, China, Singapore